Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Benmelstobart Combined With Anlotinib and Chemotherapy as Neoadjuvant Therapy Followed by Surgery and Postoperative Radiotherapy in Patients With Locally Advanced Oral Cancer

NCT06848439 is registered in ClinicalTrials.gov with Jiangsu Cancer Institute & Hospital as lead sponsor.

NCT NCT06848439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06848439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Benmelstobart Combined With Anlotinib and Chemotherapy as Neoadjuvant Therapy Followed by Surgery and Postoperative Radiotherapy in Patients With Locally Advanced Oral Cancer
Lead sponsor
Jiangsu Cancer Institute & Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 15, 2025
Completion date
December 31, 2028
Enrollment
26 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immunotherapy, molecular targeted therapy, mouth neoplasms, neoadjuvant therapy